[Form 4] Astera Labs, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Astera Labs CFO Michael Truett Tate reported multiple stock sales on 08/12/2025. The Form 4 shows dispositions of 66,561, 32,374 and 1,065 shares of common stock sold at weighted-average prices of approximately $190.8154, $191.9162 and $192.5156, respectively, and an additional 278,373 shares disposed, for a combined total of 378,373 shares sold on that date. Following the reported transactions, the filing lists beneficial ownership totals of 434,935, 402,561 and 401,496 shares in related entries, with indirect ownership noted by the Tate 1997 Living Trust and by GlobalStar DAF. The filing includes weighted price ranges for each sale series and a signature by an attorney-in-fact dated 08/14/2025. The reporting person disclaims beneficial ownership of trust- and DAF-held shares except for any pecuniary interest.

Positive

• Timely, detailed disclosure of multiple sales including weighted-average price ranges
• Clear identification of indirect ownership via the Tate 1997 Living Trust and GlobalStar DAF with standard disclaimers

Negative

• Large insider dispositions totaling 378,373 shares on 08/12/2025, which may be material to some investors
• No explanatory context in the filing about the reason for the sales (e.g., 10b5-1 plan or liquidity needs)

Insights

Financial Analyst

TL;DR: Significant insider selling disclosed; sale prices clustered near $191, no additional context provided.

The Form 4 documents sizable dispositions by the company's CFO totaling 378,373 shares on 08/12/2025 at weighted average prices around $190.50–$192.55. The filing supplies precise weighted-average price ranges and post-transaction beneficial ownership figures, which supports transparent reporting. There is no commentary in the filing about the purpose of the sales or any corresponding purchases, so the transactions should be interpreted as reported events without further context. For valuation impact, investors would compare the sale volume to outstanding shares and recent trading volume outside this form.

Corporate Governance Expert

TL;DR: Filing meets disclosure requirements; trustee-held shares and disclaimers are clearly stated.

The Form 4 correctly identifies the reporting person as an officer (CFO) and notes indirect ownership through the Tate 1997 Living Trust and the GlobalStar DAF with the customary disclaimer of beneficial ownership. Multiple price-range footnotes provide granular execution detail, and the form is signed by an attorney-in-fact. The filing does not allege any related-party transactions or plans (e.g., 10b5-1), so from a governance perspective the document fulfills Section 16 reporting obligations but does not explain the economic or corporate rationale for the dispositions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tate Michael Truett

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		S		66,561	D	$190.8154(1)	434,935	I	By Tate Trust(2)
Common Stock	08/12/2025		S		32,374	D	$191.9162(3)	402,561	I	By Tate Trust(2)
Common Stock	08/12/2025		S		1,065	D	$192.5156(4)	401,496	I	By Tate Trust(2)
Common Stock								7,500	I	GlobalStar DAF(5)
Common Stock								278,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $190.5000 to $191.4950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $191.5000 to $192.4900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $192.5000 to $192.5500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. These shares are directly owned by the GlobalStar DAF, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Astera Labs (ALAB) CFO Michael T. Tate sell on 08/12/2025?

The Form 4 reports dispositions of 66,561, 32,374, 1,065 and 278,373 shares of Astera Labs common stock, totaling 378,373 shares sold on 08/12/2025.

At what prices were the ALAB shares sold in the Form 4?

The filing shows weighted-average prices of approximately $190.8154, $191.9162 and $192.5156 for the reported sale series, with execution price ranges noted in footnotes.

Does the Form 4 indicate indirect ownership for Michael Tate?

Yes. The filing states certain shares are owned indirectly by the Tate 1997 Living Trust and some shares are owned by the GlobalStar DAF, with the reporting person disclaiming beneficial ownership except for any pecuniary interest.

When was the Form 4 signed and filed?

The Form 4 is signed by an attorney-in-fact, Philip Mazzara, with a signature date of 08/14/2025 as shown on the filing.

Does the filing state the sales were made under a 10b5-1 plan?

No. The Form 4 does not indicate that these transactions were made pursuant to a 10b5-1 plan or other written plan in the provided content.